Bristol Myers Squibb presents new interim pooled long-term safety and metabolic outcome data from the EMERGENT program evaluating KarXT in schizophrenia at the 2024 Annual Meeting of the International...
EMERGENT-3 trial showed xanomeline-trospium was effective in improving schizophrenia symptoms at 52 weeks, for participants who took either placebo or KarXT in acute trials.
Bristol Myers Squibb today announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia. Long-term...
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics. The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. "Current antipsychotic treatments are associated with a number of adverse effects, including adverse metabolic profiles, increases in weight ... and there still remains a need for more effective treatments," said Roland Chen, SVP, global drug development for immunology, neuroscience and cardiovascular development at Bristol Myers.
BMS' schizophrenia drug shows long-term benefit with new data fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 weeks
More than 75% of participants achieved
 KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment
A majority of patients ...
By Sneha S K (Reuters) - Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped ...